Advertisement

 

 

High-potency phenylquinoxalinone cystic fibrosis transmembrane conductance regulator (CFTR) activators.

High-potency phenylquinoxalinone cystic fibrosis transmembrane conductance regulator (CFTR) activators.
Author Information (click to view)

Son JH, Zhu JS, Phuan PW, Cil O, Teuthorn AP, Ku CK, Lee S, Verkman AS, Kurth MJ,


Son JH, Zhu JS, Phuan PW, Cil O, Teuthorn AP, Ku CK, Lee S, Verkman AS, Kurth MJ, (click to view)

Son JH, Zhu JS, Phuan PW, Cil O, Teuthorn AP, Ku CK, Lee S, Verkman AS, Kurth MJ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Journal of medicinal chemistry 2017 02 23() doi 10.1021/acs.jmedchem.6b01759
Abstract

We previously identified phenylquinoxalinone CFTRact-J027 (4) as a cystic fibrosis transmembrane conductance regulator (CFTR) activator with an EC50 of ~200 nM, and demonstrated its therapeutic efficacy in mouse models of constipation. Here, structure-activity studies were done on 36 synthesized phenylquinoxalinone analogs to identify compounds with improved potency and altered metabolic stability. Synthesis of the phenylquinoxalinone core was generally accomplished by condensation of 1,2-phenylenediamines with substituted phenyloxoacetates. Structure-activity studies established, among other features, the privileged nature of a properly positioned nitro moiety on the 3-aryl group. Synthesized analogs showed improved CFTR activation potency compared to 4 with EC50 down to 21 nM and with greater metabolic stability. CFTR activators have potential therapeutic indications in constipation, dry eye, cholestatic liver diseases, and inflammatory lung disorders.

Submit a Comment

Your email address will not be published. Required fields are marked *

8 + 5 =

[ HIDE/SHOW ]